Schilke Tobin's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Mar 4, 2026
- Accession no.
- 0001628280-26-014772
- Filed
- Mar 4, 2026
- Trade date
- Mar 3, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $266.3K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schilke TobinCIK 0001678984 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Common Stock | SSaleDisposed | −6,713 | $39.67F2 | −$266,304.71 | 78,121 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.